Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study
出版年份 2014 全文链接
标题
Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 59, Issue 8, Pages 1177-1184
出版商
Oxford University Press (OUP)
发表日期
2014-07-04
DOI
10.1093/cid/ciu515
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characterization of Binding of Raltegravir to Plasma Proteins
- (2013) Caroline Barau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
- (2013) B. Hernandez-Novoa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C
- (2011) J. Macias et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects
- (2011) D. Cattaneo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
- (2011) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients
- (2011) Dario Cattaneo et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
- (2010) Aurélie Barrail-Tran et al. AIDS
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive Drugs
- (2009) L. Tricot et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial
- (2009) Nathalie De Castro et al. CLINICAL INFECTIOUS DISEASES
- Effects of Omeprazole on Plasma Levels of Raltegravir
- (2009) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
- High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial
- (2009) Y. Yazdanpanah et al. CLINICAL INFECTIOUS DISEASES
- A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
- (2009) A. Fayet et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started